# Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

> **NCT01556438** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 16 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Tabalumab
- **DRUG:** Bortezomib IV
- **DRUG:** Bortezomib SC
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01556438
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-02
- **Final completion:** 2015-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556438, "Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT01556438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*